301207.SZShenzhen
Hualan Biological Vaccine Inc.
¥16.39
ListedFeb 18, 2022
SectorHealthcare
IndustryBiotechnology
CountryChina
Employees708
State-| CityXinxiang| AddressJia No. 1-1, Hualan Avenue| Phone86 37 3355 9909
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines. In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.

Key Indicators

Key financial and dividend metrics for this stock.

?
P/E Ratio
56.3
?
Div. Rate
¥0.80
?
Div. Yield
4.44%
?
Payout Ratio
253.89%
?
Max Consec. Div. Years
4 years
?
Longest Consec. Div.
3 years
?
Div. Coverage
100%
?
Div. Stability Rate
0.44
?
Div. Growth Rate
100.00%
?
Score
87

Dividend History

Historical dividend payments by ex-dividend date.

Oct 27, 2025
¥ 0.6000
Jun 17, 2025
¥ 0.2000
Jun 14, 2024
¥ 0.6000
Jun 7, 2023
¥ 0.3000
Jun 16, 2022
¥ 0.1333

Peer Companies

Other stocks in the same sector.

The app download will be available in the next version. Stay tuned!